Liver Transplants from Donors with Schistosomiasis: Clinical and Epidemiological Profile of Patients at Clinics Hospital of São Paulo, Brazil / Transplantes Hepáticos de Doadores com Esquistossomose: Perfil Clínico e Epidemiológico de Pacientes do Hospital das Clínicas, São Paulo, Brasil

Organ transplantation is a surgical procedure that consists of awarding an organ. Considering that the transplantation of an organ or tissue is very competitive, due to the low rate of donors and as the function of the liver is preserved even in controlled schistosomatic fibrosis, it is possible to donate the organ even with the liver infected by verminosis. By analyzing the prevalence and evolution of liver donors with schistosomiasis in liver transplants performed at Hospital das Clínicas, Faculty of Medicine, University of São Paulo - HCFMUSP. This is a descriptive study, consisting of a series of cases, with a retrospective and cross-sectional analysis. The study evaluated the medical records of patients being followed up at the Liver Transplant Outpatient Clinic, at HCFMUSP, from January 2002 to December 2020. The Department of Pathology at USP found 16 patients with records of schistosomiasis reports, of which only one was effective as a donor, since the other patients were excluded due to the state of law of the organ. An analysis showed that almost all donors were men with schistosomiasis with a mean age of 52.55 years. In this context, there was a prevalence of a case of a liver donor with the hepatointestinal form of schistosomiasis, later the organ was transplanted, and the recipient, presented a good evolution until this moment, having been analyzed clinically and laboratory. It is noteworthy that this is the first HCFMUSP study that evaluates liver donors with schistosomiasis mansoni and the evolution of the respective recipient. (AU)

O transplante de órgãos é um procedimento cirúrgico que consiste na reposição de um órgão. Haja vista que o transplante de um órgão ou tecido é muito concorrido, em decorrência da baixa taxa de doadores e como a função do fígado está preservada mesmo na fibrose esquistossomatica avançada é possível doador o órgão mesmo com o fígado infectado pela verminose. O objetivo desse estudo foi analisar a prevalência e evolução de doadores fígado, portadores de esquistossomose, nos transplantes hepáticos realizados no Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo - HCFMUSP. Trata-se de um estudo descritivo, composto por uma série de casos, sendo a analise retrospectiva e de corte transversal. O estudo avaliou os prontuários de pacientes em seguimento no Ambulatório de Transplante hepático, do HCFMUSP, no período de janeiro de 2002 a dezembro de 2020. O departamento de Patologia da USP constatou 16 pacientes com registros de laudos de esquistossomose, dos quais somente um foi efetivado como doador, uma vez que os outros pacientes foram excluídos em razão do estado de deterioração do órgão. A análise mostrou que quase a totalidade dos doadores eram homens com esquistossomose com idade média de 52,55 anos. Dentro desse contexto, houve a prevalência de um caso de um doador hepático portador da forma hepatointestinal de esquistossomose, posteriormente o órgão foi transplantado, e o receptor, apresentou uma boa evolução até este momento tendo sido analisado clinicamente e laboratorialmente. Vale ressaltar, que este é o primeiro estudo do HCFMUSP que avalia doadores de hepáticos portadores de esquistossomose mansoni e a evolução do respectivo receptor. (AU)

Descripción de polimorfismos genéticos en CYP3A5 y MDR-1 y su impacto en el rechazo agudo clínico de pacientes trasplantados de hígado del Hospital San Vicente Fundación Rionegro / Description of genetic polymorphisms in CYP3A5 and MDR-1 and their impact on clinical acute rejection in liver transplant patients at Hospital San Vicente Fundación Rionegro

Introducción. El tacrolimus es un medicamento inmunosupresor ampliamente usado en trasplante hepático, que presenta una gran variabilidad interindividual la cual se considera asociada a la frecuencia de polimorfismos de CYP3A5 y MDR-1. El objetivo de este estudio fue evaluar la frecuencia de los polimorfismos rs776746, rs2032582 y rs1045642 y su asociación con rechazo clínico y toxicidad farmacológica. Métodos. Se incluyeron pacientes inmunosuprimidos con tacrolimus a quienes se les realizó trasplante hepático en el Hospital San Vicente Fundación Rionegro entre 2020 y 2022, con supervivencia mayor a un mes. Se evaluaron las variables clínicas, rechazo agudo y toxicidad farmacológica. Se secuenciaron los genes de estudio mediante PCR, comparando la expresión o no en cada uno de los pacientes. Resultados. Se identificaron 17 pacientes. El 43 % de los pacientes se clasificaron como CYP3A5*1/*1 y CYP3A5*1/*3, entre los cuales se encontró asociación con aumento en la tasa de rechazo agudo clínico, al comparar con los pacientes no expresivos (100 % vs. 44 %, p=0,05); no hubo diferencias en cuanto a la toxicidad farmacológica u otros desenlaces. Se encontró el polimorfismo rs2032582 en un 50 % y el rs1045642 en un 23,5 % de los pacientes, sin embargo, no se identificó asociación con rechazo u otros eventos clínicos. Conclusiones. Se encontró una asociación entre el genotipo CYP3A5*1/*1 y CYP3A5*1/*3 y la tasa de rechazo clínico. Sin embargo, se requiere una muestra más amplia para validar estos datos y plantear modelos de medicina personalizada.

Introduction. Tacrolimus is an immunosuppressive drug widely used in liver transplantation, which presents great interindividual variability which is considered associated with the frequency of CYP3A5 and MDR-1 polymorphisms. The objective of this study was to evaluate the frequency of the rs776746, rs2032582 and rs1045642 polymorphisms and their association with clinical rejection and drug toxicity. Methods. Immunosuppressed patients with tacrolimus who underwent a liver transplant at the Hospital San Vicente Fundación Rionegro between 2020 and 2022 were included, with survival of more than one month. Clinical variables, acute rejection and pharmacological toxicity were evaluated. The study genes were sequenced by PCR, comparing their expression or not in each of the patients. Results. Seventeen patients were identified. 43% of the patients were classified as CYP3A5*1/*1 and CYP3A5*1/*3, among which an association was found with increased rates of clinical acute rejection when compared with non-expressive patients (100% vs. 44%, p=0.05). There were no differences in drug toxicity or other outcomes. The rs2032582 polymorphism was found in 50% and rs1045642 in 23.5% of patients; however, no association with rejection or other clinical events was identified. Conclusions. An association was found between the CYP3A5*1/*1 and CYP3A5*1/*3 genotype and the clinical rejection rate. However, a larger sample is required to validate these data and propose models of personalized medicine.

Is Iron Overload Associated with Worse Outcomes in Patients with Chronic Liver Disease Undergoing Liver Transplantation?

ABSTRACT Background: Iron overload is frequent in patients with chronic liver disease, associated with shorter survival after liver transplantation in patients with hereditary hemochromatosis. Its effect on patients without hereditary hemochromatosis is unclear. The aim of the study was to study the clinical impact of iron overload in patients who underwent liver transplantation at an academic tertiary referral center. Methods: We performed a retrospective cohort study including all patients without hereditary hemochromatosis who underwent liver transplantation from 2015 to 2017 at an academic tertiary referral center in Mexico City. Explant liver biopsies were reprocessed to obtain the histochemical hepatic iron index, considering a score ≥ 0.15 as iron overload. Baseline characteristics were compared between patients with and without iron overload. Survival was estimated using the Kaplan-Meier method, compared with the log-rank test and the Cox proportional hazards model. Results: Of 105 patients included, 45% had iron overload. Viral and metabolic etiologies, alcohol consumption, and obesity were more frequent in patients with iron overload than in those without iron overload (43% vs. 21%, 32% vs. 22%, p = 0.011; 34% vs. 9%, p = 0.001; and 32% vs. 12%, p = 0.013, respectively). Eight patients died within 90 days after liver transplantation (one with iron overload). Complication rate was higher in patients with iron overload versus those without iron overload (223 vs. 93 events/100 person-months; median time to any complication of 2 vs. 3 days, p = 0.043), without differences in complication type. Fatality rate was lower in patients with iron overload versus those without iron overload (0.7 vs. 4.5 deaths/100 person-months, p = 0.055). Conclusion: Detecting iron overload might identify patients at risk of early complications after liver transplantation. Further studies are required to understand the role of iron overload in survival.

Aplicabilidad del índice de fragilidad hepática en pacientes cirróticos evaluados para trasplante / Applicability of the liver frailty index in cirrhotic patients evaluated for transplantation

Introducción. En las últimas décadas se han desarrollado diferentes scores y modelos para predecir el pronóstico en pacientes con enfermedad hepática crónica avanzada. Los más reconocidos y utilizados son el sistema de estadificación de Child-Pugh (CP) y el score de MELD, pero estos carecen de herramientas para evaluar objetivamente otros factores pronósticos. Por este motivo, se ha incorporado el concepto de fragilidad a la hepatología clínica. El objetivo de este artículo es examinar la aplicabilidad del índice de fragilidad hepática (IFH) en pacientes con cirrosis evaluados para trasplante hepático en Uruguay. Metodología. Estudio observacional, descriptivo y retrospectivo en el Servicio de Enfermedades Hepáticas del Hospital Central de las Fuerzas Armadas (HCFFAA) de enero de 2018 a diciembre de 2021. Resultados. Se evaluaron un total de 78 pacientes, excluyéndose 19 de estos, culminando con una muestra final de 59 pacientes. La edad media fue de 52 años, siendo el 66 % hombres. La principal etiología de la cirrosis fue la alcohólica, y la comorbilidad más frecuente fue el sobrepeso/obesidad (66 %). La media de IFH fue de 4,03 ± 0,45. El 90 % de los pacientes eran prefrágiles, el 10 % frágiles y ningún paciente fue clasificado como no frágil. El 76 % presentaba un estadio avanzado de la enfermedad al momento de la evaluación 42 % CP estadio B, 34 % CP C, 24 % CP A, con una media de MELD-Na de 17,8 ± 7,6. El 17 % tuvo complicaciones infecciosas. La mortalidad global (n=78) fue del 12 %, y la de los pacientes con IFH calculado fue del 22 %. Conclusiones. El cálculo del IFH es realizable en cirróticos como herramienta objetiva que brinda una mirada integral del paciente. A mayor severidad de la cirrosis, mayor es el IFH. Sin embargo, este índice no parece ser un predictor de la eventual realización del trasplante hepático, ni de muerte en lista de espera en nuestros pacientes.

Introduction. In recent decades, several scores and models have been proposed to predict prognosis in patients with advanced chronic liver disease. The most recognized and used are the Child-Pugh (CP) and the Model for End-stage Liver Disease (MELD) scores, but they lack tools to objectively evaluate other prognostic factors. For this reason, the concept of fragility has been incorporated into clinical hepatology. The objective of this study was to evaluate the applicability of the liver frailty index (LFI) in patients with cirrhosis evaluated for liver transplantation in Uruguay. Methodology. Observational, descriptive and retrospective study at the Hospital Central de las Fuerzas Armadas (HCFFAA) Liver Disease Service from January 2018 to December 2021. Results. A total of 78 patients were evaluated, 19 were excluded, culminating in a final sample of 59 patients. The mean age was 52 years, with 66% being men. The main etiology of cirrhosis was alcoholic and the most frequent comorbidity was overweight/obesity (66%). The mean LFI was 4.03 ± 0.45. 90% of patients were pre-fragile, 10% were fragile, and no patient was classified as non-fragile. 76% had an advanced stage of the disease at the time of evaluation: 42% CP stage B, 34% CP C, 24% CP A, with a mean MELD-Na of 17.8 ± 7.6. 17% had infectious complications. Overall mortality (n=78) was 12%, and that of patients with calculated LFI was 22%. Conclusions. The LFI can be calculated in cirrhotic patients, and it is an objective tool that provides a comprehensive view of the patient. LFI depends on the severity of the cirrhosis. However, this index is not a predictor of liver transplantation or death on the waiting list in our patients.

Caracterización clínico-epidemiológica de pacientes con enfermedad hepática esteatósica asociada a disfunción metabólica previa al trasplante en un hospital de cuarto nivel / Clinical-epidemiological characterization of patients with steatotic liver disease associated with metabolic dysfunction prior to transplantation in a fourth level hospital

Introducción. La enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) se ha convertido en la enfermedad hepática crónica más frecuente en los países occidentales, causando un aumento en los costos y en la ocupación hospitalaria. La caracterización integral previa al trasplante hepático en pacientes con MASLD es una gran interrogante, especialmente en nuestro medio. El objetivo del presente estudio fue realizar la caracterización clínico-epidemiológica de pacientes trasplantados por cirrosis hepática (CH) descompensada o carcinoma hepatocelular (CHC) asociado a MASLD. Metodología. Se desarrolló un estudio observacional retrospectivo, descriptivo, de corte transversal en el Servicio de Hepatología del Hospital Pablo Tobón Uribe en Medellín, Colombia. Se incluyeron pacientes mayores de 17 años, con diagnóstico de CH o de CHC asociado a MASLD que fueron trasplantados entre los años 2004 a 2017. Resultados. Se encontraron 84 pacientes que fueron trasplantados con esas características. La edad promedio de los pacientes fue de 59±10,5 con una mayor proporción significativa de hombres sobre mujeres, llegando casi al 70 %. Con relación a las comorbilidades, se encontró que el sobrepeso/obesidad, la hipertensión arterial y la diabetes mellitus tipo 2 fueron un hallazgo en el 44,1 %, 33,3 % y 33,3 %, respectivamente. Por otro lado, el 14,5 %, el 33,7 % y el 51,8 % presentaron un Child-Pugh A, B y C, respectivamente. La media del puntaje MELD fue de 18,9±6,26. Con respecto a las complicaciones de la cirrosis, el 77,4 % de los pacientes presentó ascitis, el 61,9 % encefalopatía hepática, el 36,9 % hemorragia del tracto digestivo superior y el 29,8 % peritonitis bacteriana espontánea. Conclusión. Los resultados expuestos mostraron nuestra experiencia en trasplante hepático en pacientes con CH y CHC asociado a MASLD. Se debe realizar una evaluación multidisciplinaria antes y después del trasplante en estos pacientes, haciendo especial énfasis en el manejo de la disfunción metabólica y sus componentes, entre los que se destacan la obesidad y la diabetes mellitus.

Introduction. Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most frequent chronic liver disease in Western countries, causing increased costs and hospital occupancy. The comprehensive pre-transplant characterization in patients with MASLD is a major question, especially in our setting. The aim of the present study was to perform the clinical-epidemiological characterization of transplanted patients with decompensated liver cirrhosis (LC) or hepatocellular carcinoma (HCC) associated with MASLD. Methodology. A retrospective, descriptive, cross-sectional observational study was carried out in the Hepatology Department of the Pablo Tobón Uribe Hospital in Medellin, Colombia. Patients over 17 years of age, with a diagnosis of LC or HCC associated with MASLD who were transplanted between 2004 and 2017 were included. Results. We found 84 patients who were transplanted with these characteristics. The mean age of the patients was 59±10.5 with a significantly higher proportion of men over women, reaching almost 70%. Regarding comorbidities, overweight/obesity, arterial hypertension, and type 2 diabetes mellitus were found in 44.1%, 33.3%, and 33.3%, respectively. On the other hand, 14.5%, 33.7%, and 51.8% had Child-Pugh A, B, and C, respectively. The mean MELD score was 18.9±6.26. Regarding complications of cirrhosis, 77.4% of patients developed ascites, 61.9% hepatic encephalopathy, 36.9% upper gastrointestinal tract hemorrhage, and 29.8% spontaneous bacterial peritonitis. Conclusion. The above results showed our experience of liver transplantation in patients with LC and HCC associated with MASLD. A multidisciplinary evaluation should be performed before and after transplantation in these patients, with special emphasis on the management of metabolic dysfunction and its components, including obesity and diabetes mellitus.

Liver retransplantation: prognostic scores and results in the state of paraná / Retransplante de fígado: escores prognósticos e resultados no estado do paraná

ABSTRACT BACKGROUND: Hepatic retransplantation is associated with higher morbidity and mortality when compared to primary transplantation. Given the scarcity of organs and the need for efficient allocation, evaluating parameters that can predict post-retransplant survival is crucial. AIMS: This study aimed to analyze prognostic scores and outcomes of hepatic retransplantation. METHODS: Data on primary transplants and retransplants carried out in the state of Paraná in 2019 and 2020 were analyzed. The two groups were compared based on 30-day survival and the main prognostic scores of the donor and recipient, namely Model for End-Stage Liver Disease (MELD), MELD-albumin (MELD-a), Donor MELD (D-MELD), Survival Outcomes Following Liver Transplantation (SOFT), Preallocation Score to Predict Survival Outcomes Following Liver Transplantation (P-SOFT), and Balance of Risk (BAR). RESULTS: A total of 425 primary transplants and 30 retransplants were included in the study. The main etiology of hepatopathy in primary transplantation was ethylism (n=140; 31.0%), and the main reasons for retransplantation were primary graft dysfunction (n=10; 33.3%) and hepatic artery thrombosis (n=8; 26.2%). The 30-day survival rate was higher in primary transplants than in retransplants (80.5% vs. 36.7%, p=0.001). Prognostic scores were higher in retransplants than in primary transplants: MELD 30.6 vs. 20.7 (p=0.001); MELD-a 31.5 vs. 23.5 (p=0.001); D-MELD 1234.4 vs. 834.0 (p=0.034); SOFT 22.3 vs. 8.2 (p=0.001); P-SOFT 22.2 vs. 7.8 (p=0.001); and BAR 15.6 vs. 8.3 (p=0.001). No difference was found in terms of Donor Risk Index (DRI). CONCLUSIONS: Retransplants exhibited lower survival rates at 30 days, as predicted by prognostic scores, but unrelated to the donor's condition.

RESUMO RACIONAL: O retransplante hepático está associado a maior morbimortalidade do que o transplante primário. Dada a escassez de órgãos e a necessidade de alocação eficiente, avaliar parâmetros que possam prever a sobrevida pós-retransmissão é crucial. OBJETIVOS: Analisar os resultados dos retransplantes hepáticos em relação aos principais escores prognósticos. MÉTODOS: Foram analisados os transplantes primários e os retransplantes realizados no Estado do Paraná nos anos de 2019 e 2020. Os dois grupos foram comparados em relação à sobrevida em 30 dias e aos principais escores prognósticos do doador e do receptor: Model for End-Stage Liver Disease (MELD), MELD-albumin (MELD-a), Donor MELD (D-MELD), Survival Outcomes Following Liver Transplantation (SOFT), Preallocation Score to Predict Survival Outcomes Following Liver Transplantation (P-SOFT) e Balance of Risk (BAR). RESULTADOS: Foram incluídos 425 transplantes primários e 30 retransplantes. A principal etiologia da hepatopatia no transplante primário dos pacientes retransplantados foi o etilismo (n=140; 31,0%), e os principais motivos para os retransplantes foram o não funcionamento primário do enxerto (n=10; 33,3%) e a trombose da artéria hepática (n=8; 26,2%). A sobrevida em 30 dias foi maior nos transplantes primários em relação aos retransplantes (80,5% vs 36,7%; p=0,001). Os escores prognósticos foram mais elevados nos retransplantes em relação aos transplantes primários: MELD 30,6 vs 20,7 (p=0,001); MELD-a 31,5 vs 23,5 (p=0,001); D-MELD 1234,4 vs 834,0 (p=0,034); SOFT 22,3 vs 8,2 (p=0,001); P-SOFT 22,2 vs 7,8 (p=0,001); e BAR 15,6 vs 8,3 (p=0,001). Não foi observada diferença em relação ao Índice de Risco do Doador. CONCLUSÕES: Os retransplantes apresentam menor sobrevida em 30 dias, prevista nos escores prognósticos, porém sem relação com a qualidade dos doadores.

Características e desfechos clínicos de pacientes com COVID-19 grave e cirrose ou transplante de fígado em um centro quaternário brasileiro / Clinical characteristics and outcomes of patients with severe covid-19 and cirrhosis or liver transplant in a brazilian quaternary center

ABSTRACT Background: Specific associations between liver cirrhosis and liver transplant with poorer outcomes in COVID-19 are still not completely clear. Objective: We aimed to evaluate the clinical characteristics and outcomes of patients with severe COVID-19 and cirrhosis or liver transplant in Sao Paulo, Brazil. Methods: A retrospective observational study was conducted in a quaternary hospital. Patients with COVID-19 and liver cirrhosis or liver transplant were selected. The clinical and demographic characteristics, as well as the outcomes, were assessed using electronic records. Results: A total of 46 patients with COVID-19 and liver condition were included in the study. Patients with liver cirrhosis had significantly more endotracheal intubation and a higher relative risk of death than liver transplant recipients. Patients with higher MELD-Na scores had increased death rates and lower survival probability and survival time. Conclusion: Patients with liver cirrhosis, especially those with higher MELD-Na scores, had poorer outcomes in COVID-19. Liver transplant recipients do not seem to be linked to poorer COVID-19 outcomes.

RESUMO Contexto: Associações específicas entre cirrose hepática ou transplante de fígado e piores desfechos na COVID-19 ainda não estão completamente claras. Objetivo: Nosso objetivo foi avaliar as características e desfechos clínicos de pacientes com COVID-19 grave e cirrose ou transplante de fígado em São Paulo, Brasil. Métodos: Foi realizado um estudo observacional retrospectivo em um hospital quaternário. Foram selecionados pacientes com COVID-19 e cirrose hepática ou transplante de fígado. As características clínicas e demográficas, bem como os desfechos, foram avaliados por meio de prontuários eletrônicos. Resultados: Um total de 46 pacientes com COVID-19 e problemas hepáticos foram incluídos no estudo. Pacientes com cirrose hepática tiveram significativamente mais intubação endotraqueal e maior risco relativo de morte do que pacientes transplantados. Pacientes com pontuações MELD-Na mais altas apresentaram taxas de mortalidade aumentadas e menor probabilidade e tempo de sobrevivência. Conclusão: Pacientes com cirrose hepática, especialmente aqueles com escores MELD-Na mais elevados, tiveram piores desfechos na COVID-19. Os pacientes com transplante hepáticos não parecem estar associados a piores desfechos da COVID-19.

Oral candidiasis in liver transplant patients: species identification and antifungal susceptibility profile

ABSTRACT Objective This study aimed to verify oral candidiasis, identify the causative species, and investigate the antifungal susceptibility of yeasts isolated from liver transplant patients. Methods A descriptive analysis of 97 patients who underwent liver transplantation was conducted at a hospital. Two clinical examinations (Collections A and B) of the oral cavity were performed. Oral material was collected from all patients, inoculated in Sabouraud Dextrose Agar, and incubated at 35℃ for 48 hours. Samples were identified by molecular sequencing of the internal trascribed space region of rDNA. Results An antifungal susceptibility test with fluconazole, amphotericin B, and micafungin was performed using the Clinical and Laboratory Standards Institute yeast broth microdilution method. Among the patients, 15 presented with oral candidiasis: eight in Collection A and seven in Collection B. The primary type of candidiasis was atrophic, followed by pseudomembranous candidiasis. The most prevalent species was Candida albicans (nine), followed by Candida glabrata (three), Candida tropicalis (two), and Candida dubliniensis (one). Regarding susceptibility to fluconazole, of the 15 samples, 11 were susceptible, three were susceptible in a dose-dependent manner, and one was resistant. Conclusion The most commonly identified type of candidiasis was atrophic, with C. albicans and C. glabrata being the most prevalent causative species. One fluconazole-resistant isolate each of C. tropicalis and C. albicans were identified.

Acute-on-chronic liver failure: a retrospective review of cases at a transplantation center in Brazil

Purpose: Acute-on-chronic liver failure (ACLF) is a leading cause of death in cirrhotic patients. This study aims to describe the outcomes of in-patients with ACLF at a liver transplantation (LT) center in Brazil. Methods: Retrospective study analyzing patient data from 2017 to 2022. Re-transplant cases and patients without previous chronic liver disease were excluded. The ACLF diagnosis was based on the European Association for the Study of the Liver-Chronic Liver Failure criteria and assessments repeated on days 3 and 7 after the initial diagnosis. Results: Among 381 patients, 10.49% (n = 40) were diagnosed with ACLF. Bacterial infection was the most common precipitating factor (45%). Kidney failure occurred in 65% of the cases. The 28-day mortality rate was 35% and varied according to ACLF severity at diagnosis, from single organ failure (ACLF-1) at 22% to three organ failures (ACLF-3) at 60%. Eighteen patients (45%) were transplanted with a 100% 28-day survival rate. For ACLF-3 cases at diagnosis (n = 15), the 28-day and 1-year survival rates with a transplant (n = 4) were 100% and 80%, respectively, and without transplant (n = 11), 10 and 0%, respectively. Conclusions: ACLF was associated with high mortality rates. LT was an effective therapeutic option, particularly for ACLF-3 cases.

Impact of educational intervention on understanding health recommendations after liver transplantation / El impacto de una intervención educativa sobre la comprensión de las recomendaciones sanitarias stras un trasplante de hígado / Impacto de intervenção educativa na compreensão sobre recomendações para saúde após transplante de fígado

ABSTRACT Objectives: to evaluate the impact of educational intervention on understanding health recommendations after liver transplantation. Methods: randomized and prospective clinical trial, with 68 liver transplant recipients in two institutions. The level of understanding was assessed using a statement agreement scale and the understanding score was classified. Chi-square test was used to compare groups. Results: the level of understanding was reasonable in 77.9% of patients, 73.5% in the Control Group and 82.3% in the Intervention Group (p=0.399). For topics covered after educational action, there were more than 80% correct answers regarding nutrition, frequent hydration, usage and function of immunosuppressants. However, there were less than 10% correct answers regarding hand hygiene, contact with animals and crowds of people. The use of the patient's audio, visual and tactile resources led to improved understanding of skin care (p=0.014). Conclusions: the level of understanding acquired regarding health recommendations was only reasonable.

RESUMEN Objetivos: evaluar el impacto de una intervención educativa sobre la comprensión de las recomendaciones sanitarias tras un trasplante de hígado. Métodos: se trata de un ensayo clínico prospectivo aleatorizado con 68 pacientes trasplantados de hígado de dos instituciones. Se evaluó el nivel de conocimiento mediante una escala de acuerdo con las afirmaciones y se clasificó la puntuación de la comprensión. Se utilizó la prueba de chi-cuadrado para comparar los grupos. Resultados: el nivel de comprensión fue razonable en el 77,9% de los pacientes, con el 73,5% del Grupo de Control y el 82,3% del Grupo de Intervención (p=0,399). En cuanto a los temas tratados tras la actividad educativa, más del 80% tenía conocimiento sobre alimentación, hidratación frecuente, uso y función de los inmunosupresores. Sin embargo, hubo menos de un 10% de respuestas correctas sobre la higiene de las manos, el contacto con animales y las aglomeraciones de personas. La utilización de los recursos auditivos, visuales y táctiles del paciente mejoró la comprensión del cuidado de la piel (p=0,014). Conclusiones: el nivel de comprensión adquirido sobre las recomendaciones sanitarias fue solo razonable.

RESUMO Objetivos: avaliar o impacto de intervenção educativa na compreensão sobre recomendações para saúde após transplante de fígado. Métodos: ensaio clínico randomizado prospectivo, com 68 transplantados de fígado em duas instituições. Avaliou-se o nível de compreensão por meio de escala de concordância de afirmativas e classificou-se o escore de compreensão. Utilizou-se teste qui-quadrado para comparação dos grupos. Resultados: o nível de compreensão foi razoável em 77,9% dos pacientes, sendo 73,5% no Grupo Controle e 82,3% no Grupo Intervenção (p=0,399). Para temas abordados após ação educativa, houve mais de 80% de acertos sobre alimentação, hidratação frequente, uso e função do imunossupressor. Entretanto, houve menos de 10% de acertos sobre higienização das mãos, contato com animais e aglomerações de pessoas. A utilização dos recursos áudio, visual e tátil do paciente ocasionou melhora na compreensão sobre cuidado com a pele (p=0,014). Conclusões: o nível de compreensão adquirido às recomendações para saúde foi apenas razoável.

Indications and outcomes of liver retransplantation in three medical centers / Indicações e resultados do retransplante hepático em três centros médicos

ABSTRACT Introduction: retransplantation is the only viable treatment for patients with irreversible graft loss. The objective of this study was to analyze the indications and outcomes of liver retransplantation in three medical centers. Methods: a total of 66 patients who underwent liver retransplantation from September 1991 to December 2021 were included in the study. A retrospective analysis was performed evaluating patients demographic, clinical, primary diagnosis, indications for and time interval to retransplantation, complications and patient survival. Results: from a total of 1293 primary liver transplants performed, 70 required one or more liver retransplant. The main indication for primary transplant was hepatitis C cirrhosis (21,2%). Hepatic artery thrombosis was the main cause of retransplantation (60,6%), with almost half (46,9%) of retransplants having occurred within 30 days from initial procedure. The average survival time after a repeat liver transplant, was 89,1 months, with confidence interval from 54 to 124,2. The 1-,5- and 10- year survival rate following liver retransplant were 48,4%, 38% and 30,1%, respectively. Male gender, primary non function as the cause for retransplant, prolonged operative time and higher MELD were associated with higher mortality. Conclusions: operative mortality and morbidity rates of liver retransplantation are higher than those of the first transplantation. Male gender, primary non function, prolonged operative time and higher MELD were associated with less favorable outcomes.

RESUMO Introdução: retransplante é o único tratamento viável para pacientes com perda irreversível do enxerto. O objetivo deste estudo foi analisar as indicações e resultados do retransplante hepático em três centros médicos. Métodos: foram incluídos no estudo 66 pacientes submetidos a retransplante hepático no período de setembro de 1991 a dezembro de 2021. Foi realizada uma análise retrospectiva avaliando dados demográficos, clínicos, diagnóstico primário dos pacientes, indicações e intervalo de tempo para retransplante, complicações e sobrevida do paciente. Resultados: de um total de 1.293 transplantes primários de fígado realizados, 70 necessitaram de um ou mais retransplantes de fígado. A principal indicação de transplante primário foi cirrose por hepatite C (21,2%). A trombose da artéria hepática foi a principal causa de retransplante (60,6%), sendo que quase metade (46,9%) dos retransplantes ocorreu dentro de 30 dias do procedimento inicial. O tempo médio de sobrevivência após retransplante de fígado foi de 89,1 meses, com intervalo de confiança de 54 a 124,2. A taxa de sobrevivência de 1,5 e 10 anos após o retransplante de fígado foi de 48,4%, 38% e 30,1%, respectivamente. Gênero masculino, disfunção primária do enxerto como causa de retransplante, tempo operatório prolongado e maior MELD foram associados a maior mortalidade. Conclusão: as taxas de mortalidade e morbidade operatórias do retransplante hepático são superiores às do primeiro transplante. Sexo masculino, disfunção primária do enxerto, tempo operatório prolongado e maior MELD foram associados a desfechos menos favoráveis.

Desarrollo de una Unidad de Cirugía Hepatobiliar Compleja y Trasplante Hepático en un hospital público: a una década de su formación / Development of a complex hepatobiliary surgery and liver transplantation unit in a public hospital: a decade after its creation

RESUMEN Antecedentes: concentrar esta patología hepatobiliar en centros especializados puede permitir bajas cifras de morbimortalidad y mejores resultados alejados. Objetivo: describir las características clínico-patológicas y los resultados de una serie de pacientes operados en los primeros 10 años de una Unidad de Cirugía Hepatobiliar Compleja y Trasplante Hepático (TH), así como la actividad científica y docente de sus integrantes. Materiales y métodos: estudio retrospectivo descriptivo. Se recopiló información de una base de datos prospectiva. Se clasificaron los procedimientos según su complejidad y se analizaron los TH, las hepatectomías y los procedimientos biliares complejos, realizados entre 2013 y 2022. Resultados: sobre 1440 procedimientos quirúrgicos, 832 fueron de alta complejidad (58%). Se realizaron 452 trasplantes hepáticos (TH), 14 (3%) de ellos hepatorrenales; la sobrevida global del trasplante fue de 83%, 77% y 75% a 1, 3 y 5 años, respectivamente. La falla primaria del injerto se observó en 5 casos (1,1%). Se efectuaron 254 hepatectomías: 58 (23%) por patología benigna, 155 (61%) por patología maligna y 41 (16%) en donante vivo relacionado para TH. La morbilidad total fue del 27% y la mortalidad intrahospitalaria de 2%. Se efectuaron 106 derivaciones biliodigestivas: 53 en pacientes con lesión quirúrgica de la vía biliar. La morbilidad a 30 días fue del 42%, en su mayoría complicaciones menores (28%). Además, se realizaron 17 duodenopancreatectomías cefálicas y 3 esplenopancreatectomías. Se realizaron múltiples publicaciones, presentaciones y cursos, y desde 2015 se implementó una residencia posbásica de la especialidad. Conclusión: la concentración de patología hepatobiliar en un centro de alta complejidad permitió alcanzar resultados satisfactorios, comparables con series extranjeras.

ABSTRACT Background: Centralizing hepatobiliary disease in specialized centers can reduce morbidity and mortality rates and improve long-term outcomes. Objective: The aim of the present study was to describe the clinical and pathological features and surgical outcomes of a series of patients operated on in the Hepatobiliary Surgery and Liver Transplantation Unit of Hospital El Cruce during its first 10 years, as well as the scientific and educational activity of its members. Material and methods: We conducted a descriptive and retrospective study. The information was retrieved from a prospective database. The procedures were classified according to their complexity. An analysis was conducted on liver transplantations (LTs), liver resections and complex biliary procedures, performed from 2013 to 2022. Results: Of 1449 surgical procedures, 832 were high-complexity interventions (58%). A total of 452 LTs were performed, 14 (3%) were combined liver and kidney transplantations; overall transplant survival was 83%, 77% and 75% at 1, 3 and 5 years, respectively. Primary graft dysfunction was observed in 5 cases (1.1%). There were 254 liver resections; 58 cases (23%) were related to benign liver diseases, 155 (61%) to malignancies, and 41 (16%) were associated with living donor transplants. Overall morbidity was 27% and in-hospital mortality was 2%. A total of 106 bilio-digestive bypass procedures were carried out, 53 in patients with bile duct injury. Thirty-day morbidity was 42%, and most cases were minor complications (28%). Other procedures included 17 cephalic pancreaticoduodenectomies and 3 splenectomies and distal pancreatectomies. We have published numerous papers, delivered presentations and courses, and implemented a fellowship program in the specialty since 2015. Conclusion: Centralizing hepatobiliary diseases at a high-complexity center led to comparable outcomes with those reported in international series.

Sofosbuvir más glecaprevir/pibrentasvir como terapia de rescate postrasplante hepático en pacientes con exposición previa a inhibidores de NS5A. Serie de casos / Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series

Resumen Antecedentes: El tratamiento de la infección crónica por el virus de la hepatitis C (VHC) con antivirales de acción directa logra tasas de respuesta virológica sostenida superiores a 95 %. Sin embargo, el manejo del fracaso virológico sigue siendo un desafío clínico y la evidencia sobre el retratamiento es limitada, especialmente en poblaciones como los receptores de trasplante hepático (TH). Objetivo: Este estudio evaluó el régimen de sofosbuvir más glecaprevir/pibrentasvir (GLE/PIB) en receptores de TH en quienes falló el régimen basado en inhibidores de la proteína no estructural 5A (NS5A). Material y métodos: Estudio retrospectivo de 111 pacientes trasplantados entre enero de 2018 y diciembre de 2020; 18 pacientes presentaron infección recurrente por VHC posterior al TH, tres de ellos tuvieron antecedentes de al menos un régimen basado en inhibidores de NS5A. Se inició terapia de rescate con sofosbuvir más GLE/PIB durante 12 semanas posterior al TH; se registraron las características basales de los pacientes y sus desenlaces. Resultados: En los tres pacientes se logró obtener una carga viral indetectable de VHC a las 12 semanas de finalizar el tratamiento. No se observaron eventos adversos graves. Conclusión: En nuestra serie, sofosbuvir más GLE/PIB durante 12 semanas demostró ser una terapia de rescate efectiva y segura posterior al TH en pacientes previamente tratados con inhibidores de NS5A.

Abstract Background: Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals achieves a sustained virologic response rates higher than 95%. However, virologic failure remains a clinical challenge, and data on retreatment are limited, especially in special populations such as liver transplant (LT) recipients. Objective: This study evaluated the sofosbuvir plus glecaprevir-pibrentasvir (GLE/PIB) regimen in LT recipients who had failed to a nonstructural protein 5A (NS5A) inhibitor-based regimen. Material and methods: Retrospective study of 111 liver transplant recipients between January 2018 and December 2020; 18 patients presented with HCV recurrent infection after LT, out of whom three had a history of at least one NS5A inhibitor-based regimen. Salvage therapy with sofosbuvir plus GLE/PIB was started for 12 weeks; baseline characteristics and outcomes were recorded. Results: All three patients (100%) achieved an undetectable HCV viral load 12 weeks after treatment completion. No serious adverse events were observed. Conclusion: In our series, sofosbuvir plus GLE/PIB for 12 weeks is an effective and safe salvage therapy after LT in patients previously treated with NS5A inhibitors.

Trasplante hepático por hemangioendotelioma hepático difuso / Liver transplantation for diffuse epithelioid hemangioendothelioma

RESUMEN El hemangioendotelioma epiteloide hepático (HEH) es un tumor vascular, de etiología no aclarada, extraordinariamente infrecuente. La ausencia de características clínicas, analíticas y radiológicas especificas dificulta su correcto diagnóstico. El tratamiento del HEH depende del tamaño y localización tumoral, la extensión extrahepática y la condición médica del paciente. Entre las posibles opciones se encuentra el trasplante hepático, que obtiene unos buenos resultados clínicos, aunque el riesgo de recidiva no es despreciable. Presentamos un nuevo caso de HEH tratado mediante trasplante hepático.

ABSTRACT Hepatic epithelioid hemangioendothelioma (HEHE) is an extremely rare vascular tumor of unclear etiology. The diagnosis is difficult due to the absence of specific clinical characteristics, laboratory tests results and radiological findings. The management of HEHE depends on tumor size, location, extrahepatic extension, and patients' medical status. Liver transplantation is one of the possible options with good clinical results, although the risk of recurrence is not negligible. We present a new case of HEHE managed with liver transplantation.

Inmunizaciones en cirrosis y trasplante hepático: Puesta al día / Vaccination for Cirrhosis and Liver Transplant Patients

Patients with cirrhosis and liver transplantation (LT) have a higher risk of infections, complications and death. Vaccines have historically been used to prevent and reduce the risk of complications from viral and bacterial infections. The population with cirrhosis and candidates for LT should be evaluated for immunity against the most relevant immuno-preventable infections, update corresponding immunizations according to the national vaccination program, and inoculate the missing vaccines based on these recommendations. In case of not reaching its inoculation prior to LT, in the post-LT period its vaccination status should be updated. All doctors involved in the health care of these patients must have knowledge about this important topic and be aware of the access and free availability for this population through the presentation of a special form incorporated into the National Immunization Program.

High versus low mean arterial pressure target in liver transplant patients. An open, controlled, single-center, randomized clinical trial - Protocol and methods (LIVER-PAM) / Alto versus baixo alvo de pressão arterial média em pacientes submetidos a transplante hepático. Um estudo clínico aberto, controlado, unicêntrico e randomizado -Protocolo e métodos (LIVER-PAM)

ABSTRACT Objective: To explain the rationale and protocol of the methods and analyses to be used in the LIVER-PAM randomized clinical trial, which seeks to understand whether a higher mean arterial pressure is capable of reducing the incidence of renal dysfunction postoperatively after liver transplantation. Methods: LIVER-PAM is an open-label, randomized, controlled, singlecenter clinical trial. Patients randomized to the intervention group will have a mean arterial pressure of 85 - 90mmHg in the initial 24 hours of postoperative management, while patients in the control group will have a mean arterial pressure of 65 - 70mmHg in the same period. A sample of 174 patients will be required to demonstrate a 20% reduction in the absolute incidence of renal dysfunction, with a power of 80% and an alpha of 0.05. Conclusion: If a 20% reduction in the absolute incidence of renal dysfunction in the postoperative period of liver transplantation is achieved with higher target mean arterial pressure in the first 24 hours, this would represent an inexpensive and simple therapy for improving current outcomes in the management of liver transplant patients. ClinicalTrials.gov Registry:NCT05068713

RESUMO Objetivo: Explicitar o racional e o protocolo de métodos e análises a serem utilizadas no ensaio clínico randomizado LIVER-PAM, que busca entender se um nível mais alto de pressão arterial média é capaz de reduzir a incidência de disfunção renal no pós-operatório de transplante hepático. Métodos: O LIVER-PAM é um estudo clínico randomizado, controlado, unicêntrico e aberto. Pacientes randomizados para o grupo intervenção terão como alvo de pressão arterial média 85 - 90mmHg nas 24 horas iniciais do manejo pós-operatório, enquanto pacientes do grupo controle terão como alvo de pressão arterial média 65 - 70mmHg no mesmo período. Uma amostra de 174 pacientes será necessária para demonstrar redução de 20% na incidência absoluta de disfunção renal, com poder de 80% e alfa de 0,05. Conclusão: Se a redução de 20% da incidência absoluta de disfunção renal no pós-operatório de transplante hepático for obtida com alvos maiores de pressão arterial média nas primeiras 24 horas, o manejo do paciente nesse cenário encontraria uma terapia barata e simples para a melhoria dos desfechos atuais. Registro Cliniclatrials.gov:NCT05068713

Baixa conscientização da vacina pós-transplante de fígado: análise e estratégia educacional / Escaso conocimiento de vacunación tras un trasplante hepático: estrategia educativa y análisis / Low post-liver transplant vaccine awareness: analysis and educational strategy

Resumo Objetivo Avaliar o conhecimento de pacientes e profissionais de saúde sobre os protocolos de vacinação no pós-transplante hepático antes e após a aplicação de uma estratégia educativa de conscientização nessa população. Métodos Os pacientes (n=124) foram submetidos à intervenção educativa através do acesso a uma página web com vídeos educativos e, para os profissionais de saúde (n=111), através de um simpósio e acesso à informação na página virtual do projeto. Para analisar o efeito da intervenção, análises qualitativas de conhecimento foram realizadas por meio de questionários antes e depois das intervenções. Resultados Entre os pacientes, predominou o sexo masculino (66,9%) e a média de idade foi de 55,2 anos (DP + 15,9). 82,2% dos pacientes procuraram uma UBS para serem vacinados e 13,7% deles, os CRIEs (Centro de Referência para Imunobiológicos Especiais). Apenas 46,7% receberam orientações sobre vacinas após o transplante hepático. Dos 111 questionários respondidos pelos profissionais de saúde, 46,5% não consultaram a carteira de vacinas, 61,3% encaminharam os pacientes para UBS e 38,7%, para um CRIE. Na análise pós-intervenção, 66,1% dos pacientes assistiram a vídeos educativos sobre vacinação. Destes, 62,2% disseram ter melhorado seu entendimento sobre as vacinas e 91,4% se sentem mais seguros para vacinar. Após a intervenção educativa, 45 profissionais de saúde responderam ao questionário. 30,4% afirmaram saber quais vacinas prescrever e 67,4% indicaram vacinas para familiares de pacientes. Conclusão A estratégia educacional proposta aplicada neste estudo mostrou aumentar a conscientização sobre os protocolos de imunização pós-transplante hepático. Isso pode contribuir para evitar o risco potencial de falta de informação e não abordagem da vacinação pelos profissionais de saúde.

Resumen Objetivo Evaluar los conocimientos de pacientes y profesionales de la salud sobre protocolos de vacunación tras un trasplante hepático, antes y después de aplicar una estrategia educativa de sensibilización en esta población. Métodos Los pacientes (n=124) fueron sometidos a la intervención educativa mediante el acceso a un sitio web con videos educativos, y los profesionales de la salud (n=11), mediante un simposio y el acceso a información en la página web del proyecto. Para analizar el efecto de la intervención, se realizaron análisis cualitativos de conocimiento con cuestionaros antes y después de la intervención. Resultados Entre los pacientes, el sexo masculino fue predominante (66,9 %) y la edad promedio fue 52,2 años (SD + 15,9). El 82,2 % de los pacientes fue a una Unidad Básica de Salud (UBS) para recibir la vacuna y el 13,7 % de ellos acudió a un Centro de Referencia para Inmunobiológicos Especiales (CRIE). Solo el 46,7 % recibió instrucciones sobre vacunación tras el trasplante hepático. De los 111 cuestionarios respondidos por profesionales de la salud, el 46,5 % no consultó el catálogo de vacunas, el 61,3 % derivó a los pacientes a una UBS y el 38,7 % a un CRIE. En el análisis posintervención, el 66,1 % de los pacientes miró los videos educativos sobre vacunación. De ellos, el 62,2 % mencionó haber mejorado su comprensión sobre vacunas y el 91,4 % se sintió más seguro para vacunarse. Después de la intervención educativa, 45 profesionales de la salud respondieron el cuestionario. El 30,4 % afirmó saber qué vacunas prescribir y el 67,4 % recomendó vacunas a familiares de los pacientes. Conclusión La estrategia educativa propuesta aplicada en este estudio demostró un aumento de conocimiento sobre los protocolos de inmunización tras un trasplante hepático. Esto pude ayudar a evitar el riesgo potencial de la falta de información y el no abordar el tema de la vacunación por parte de los profesionales de la salud.

Abstract Objective To evaluate patients' and healthcare professionals' knowledge about vaccination protocols in post-liver transplantation before and after applying an educational awareness strategy in this population. Methods Patients (n=124) underwent the educational intervention through access to a webpage containing educational videos and, for health professionals (n=111), through a symposium and access to information on the project's virtual page. To analyze the effect of the intervention, qualitative analyses of knowledge were carried out using questionnaires before and after the interventions. Results Among patients, males were predominant (66.9%) and the mean age was 55.2 years old (SD + 15.9). 82.2% of patients visited a UBS to be vaccinated and 13.7% of them the CRIEs (Reference Center for Special Immunobiologicals). Only 46.7% received orientation about vaccines after liver transplantation. From the 111 questionnaires answered by health professionals, 46.5% did not check the vaccine portfolio, 61.3% referred patients to UBS and 38.7% to a CRIE. In the post-intervention analysis, 66.1% of patients watched educational videos about vaccination. Of these, 62.2% said they had improved their understanding about vaccines and 91.4% feel safer to vaccinate. After the educational intervention, 45 health professionals answered the questionnaire. 30.4% said they knew which vaccines to prescribe, and 67.4% recommended vaccines to patients' relatives. Conclusion The proposed educational strategy applied in this study shown to increase awareness regarding the post-liver transplant immunization protocols. This may contribute to avoiding the potential risk of lack of information and failure to address vaccination by healthcare professionals.

Could retrograde reperfusion combined with washout technique broaden the applicability of marginal grafts in liver transplantation? Intra-operative and short-term outcomes of a prospective cohort / A reperfusão retrógrada combinada com a lavagem do enxerto pode ampliar a aceitabilidade de fígados limítrofes no transplante hepático? Resultados intraoperatórios e precoces de uma coorte prospectiva

ABSTRACT Introduction: many revascularization techniques were designed to reduce the imbalance of ischemia-reperfusion injury. This study's objective is to evaluate retrograde reperfusion (RR) compared to sequential anterograde reperfusion (AR), with and without the washout technique (WO). Method: this prospective cohort study collected data from 94 deceased donor orthotopic liver transplants and divided it into three groups: RR with WO (RR+WO), AP with WO (AR+WO), and AP without WO (AR). This study did not assign the reperfusion technique to the participants. The primary outcome considered the early graft dysfunction, and secondary outcomes included post-reperfusion syndrome (PRS), post-reperfusion lactate, surgery fluid balance, and vasoactive drug dose during the surgery. Results: 87 patients were submitted to the final analysis-29 in the RR+WO group, 27 in the AR+WO group, and 31 in the AR group. Marginal grafts prevalence was not significantly different between the groups (34% vs. 22% vs. 23%; p=0.49) and early graft dysfunction occurred at the same rate (24% vs. 26% vs. 19%; p=0.72). RR+WO reduced serum post-reperfusion lactate (p=0.034) and the incidence of significant PRS (17% vs. 33% vs. 55%; p=0.051), but norepinephrine dosing >0.5mcg/kg/min were not different during the surgery (20,7% vs. 29,6% vs. 35,5%, p=0.45). Conclusions: primary outcome was not significantly different between the groups; however, intraoperative hemodynamic management was safer using the RR+WO technique. We theorized that the RR+WO technique could reduce the incidence of PRS and benefit marginal graft survival following diseased donor orthotopic liver transplantation.

RESUMO Introdução: várias técnicas de reperfusão foram desenvolvidas a fim de reduzir o dano da lesão induzida por isquemia-reperfusão. Este estudo objetivou avaliar a reperfusão retrograda (RR) comparado com a reperfusão anterógrada (AR), com e sem a realização da técnica de lavagem do enxerto (WO). Métodos: coorte prospectiva com 94 transplantes ortotópicos de fígado de doador falecido divididos em três grupos: RR com WO (RR+WO), reperfusão anterógrada com WO (AR+WO), e AR sem WO (AR). Este estudo não designou a técnica de reperfusão entre os participantes. O desfecho primário considerou a disfunção precoce do enxerto, e os desfechos secundários incluíram a síndrome pós-reperfusão (SPR), lactato pós-reperfusão, balanço hídrico operatório, e uso de drogas vasoativas durante o ato peratório. Resultados: 87 pacientes foram submetidos para consolidação dos dados-29 no RR+WO, 27 no AR+WO, e 31 no AR. A prevalência de enxertos maginais não diferiu entre os grupos (34% vs 22% vs 23%; p=0,49). Disfunção precoce do enxerto ocorreu em uma proporção similar (24% vs 26% vs 19%; p=0,72). RR+WO reduziu o lactato sérico pós-reperfusão (p=0,034) e a incidência de SPR severa (17% vs 33% vs 55%; p=0,051), entretanto a infusão de noradrenalina >0,5mcg/kg/min não foi diferente durante a cirurgia (20,7% vs 29,6% vs 35,5%, p=0,45). Conclusões: o desfecho primário não diferiu significativamente entre os grupos; entretanto, o manejo hemodinâmico intra-operatório foi mais seguro no grupo RR+WO. Nós teorizamos que a técnica RR+WO pode reduzir a SPR e beneficiar enxertos marginais no transplante de fígado.

Pancreatic tuberculosis in a liver transplant recipient: a case report

ABSTRACT The pancreatic form of tuberculosis (TB) is rare and its diagnosis is challenging, since it manifests itself with non-specific symptoms and non-pathognomonic radiological findings, mimicking a neoplasia of the pancreas. Here, we report the case of a patient who had previously undergone liver transplantation and sought care for abdominal pain, weight loss, anorexia, hematochezia and postprandial fullness. Following an exploratory laparotomy and nucleic acid amplification testing on a pancreatic sample that had been collected, the patient was diagnosed with pancreatic TB. The patient received anti-tubercular pharmacological therapy and required percutaneous biliary drainage. Awareness of the possibility of a pancreatic TB diagnosis is important for clinicians. This attention should be even greater in patients who have undergone transplants, who are immunodeficient or who are from endemic areas.